GLP-1 receptor agonists are medications that copy a natural gut hormone called glucagon-like peptide-1. That hormone is released after you eat and does three main things: it tells the pancreas to release insulin when blood sugar rises, it slows how quickly the stomach empties, and it signals fullness in the brain. These drugs bind the same receptor and hold that signal far longer than the body does on its own, which is why they lower blood sugar and reduce appetite. That is the whole idea, and everything else is detail.
Why does the body’s own version not last?
Natural GLP-1 is broken down within minutes by an enzyme called DPP-4. That short life is fine for a hormone meant to respond meal by meal, but useless as a medicine. The engineering behind these drugs is mostly about resisting that breakdown. Some are peptides modified so the enzyme cannot clip them apart, which is how weekly dosing became possible. Others take a different path entirely as small molecules that fit the same receptor without being peptides at all. A 2024 review of GLP-1 and dual receptor mechanisms lays out how these design choices translate into the effects seen in the clinic, and it is a useful map if you want the biology rather than the marketing.
The receptor itself sits on many tissues, not just the pancreas. That is part of why a drug aimed at blood sugar also changes appetite and slows digestion. It is also why nausea is the most common early side effect. Slower stomach emptying and a reduced drive to eat are not accidents; they are the same mechanism people are prescribed the drug for, felt at full strength before the dose is titrated up gradually.
Which GLP-1 receptor agonists exist right now?
The category is broader than the two or three names most people recognize. Semaglutide is the best known single-receptor agonist, sold as a weekly injection for diabetes and for weight management, and also as a daily oral tablet for type 2 diabetes. Liraglutide is an older daily injectable. Dulaglutide and exenatide have been around for years in diabetes care.
Then there are the newer entries that changed the conversation. Tirzepatide is not a pure GLP-1 drug at all; it activates both the GLP-1 receptor and the GIP receptor, which is why it is called a dual agonist. Its early development was documented in a 2018 proof-of-concept paper describing the molecule then known as LY3298176, and the dual approach appears to produce larger effects on glucose and body weight than single-receptor drugs in the trials reported so far. Comparing those trials directly is tempting but not valid, because they enrolled different people under different rules.
See also: Who Is the Top Luxury Real Estate Brokerage in Dubai?
What changed with the oral small-molecule drugs?
For a long time, a real GLP-1 effect meant an injection or a fussy oral peptide that had to be taken on an empty stomach with strict timing. Orforglipron broke that pattern. It is a once-daily oral small-molecule GLP-1 receptor agonist, meaning it is not a peptide and does not carry the absorption problems that made earlier oral versions awkward. Early phase 2 results in adults with obesity were published in 2023, and a later trial of orforglipron for obesity treatment reported meaningful weight reduction. It received FDA approval in 2026 for weight management, a milestone summarized in a 2026 first-approval review, so it is a marketed product rather than an experimental one.
That matters for access. An oral tablet is easier to store, ship, and take than a refrigerated injectable, and small molecules are generally cheaper to manufacture at scale. Whether that translates into lower prices for patients is a separate question that depends on coverage, but the pharmacology finally allows for it.
How do these drugs compare at a glance?
| Drug | Target | Form | Status |
|---|---|---|---|
| Semaglutide | GLP-1 receptor | Weekly injection or daily oral | Approved |
| Liraglutide | GLP-1 receptor | Daily injection | Approved |
| Tirzepatide | GLP-1 and GIP receptors | Weekly injection | Approved |
| Orforglipron | GLP-1 receptor (small molecule) | Daily oral | Approved 2026 |
| Retatrutide | Triple receptor | Injection | Investigational |
What are they actually prescribed for?
These medicines were developed for type 2 diabetes and later approved for chronic weight management in people who meet clinical criteria. That framing is deliberate. Recent guidance has pushed to define clinical obesity as a condition in its own right, described in a 2025 paper on diagnostic criteria, rather than a number on a chart, and pharmacotherapy is placed inside a fuller treatment plan. A 2025 clinical practice guideline update on obesity pharmacotherapy and an American Gastroenterological Association guideline both position GLP-1 based drugs among the more effective options while stressing that they are tools used alongside diet, activity, and follow-up, not shortcuts that replace them.
The effects reach past weight and blood sugar. European liver guidelines on metabolic dysfunction-associated steatotic liver disease discuss these drugs in the context of a condition tightly linked to metabolic health, which is one reason interest in them keeps widening beyond their original use.
Where do compounded versions fit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that produced the trial evidence behind the brands. That is a genuine distinction, not a footnote. Some people turn to them for a predictable monthly cash price when coverage falls through. Supervised telehealth practices, including the team at FormBlends, publish flat pricing for this route with prescribing handled by a licensed clinician, which is the arrangement to look for if that path is being considered at all. The honest read is that compounding trades regulatory assurance for cost, and that trade belongs with a prescriber who knows the individual case rather than with a checkout page.
Key takeaways
- GLP-1 receptor agonists copy a gut hormone that raises insulin, slows digestion, and reduces appetite.
- The category includes single-receptor drugs, dual agonists such as tirzepatide, and now oral small molecules.
- Orforglipron was FDA-approved in 2026 as a daily oral option; retatrutide remains investigational.
- Guidelines treat these drugs as part of obesity and diabetes care, not standalone weight-loss products.
- Compounded versions are not FDA-approved and carry a different set of tradeoffs.
Frequently asked questions
What does GLP-1 actually do in the body?
GLP-1 is a gut hormone released after eating. It prompts the pancreas to release insulin when blood sugar is high, slows how fast the stomach empties, and signals fullness in the brain. GLP-1 receptor agonists are drugs built to imitate that signal for longer than the natural hormone lasts.
Are all GLP-1 receptor agonists injections?
No. Most current ones are weekly or daily injections, but oral versions exist. Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist, was approved in 2026, and an oral form of semaglutide has been available for type 2 diabetes for years.
What is the difference between a GLP-1 drug and a dual agonist?
A single GLP-1 receptor agonist acts on one receptor. A dual agonist such as tirzepatide activates both the GLP-1 and the GIP receptors, which appears to produce larger effects on blood sugar and weight in the trials reported so far.
Are compounded GLP-1 medications the same as the brands?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule, but they have not been through the approval process that generated the published trial evidence for the brands.
Who are these drugs actually prescribed for?
They were first developed for type 2 diabetes and later approved for chronic weight management in people who meet clinical criteria. Guidelines increasingly place them within broader treatment of obesity and related metabolic conditions rather than as standalone weight-loss products.
